Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion

JINGGANG MO1,2*, MEIHUA LIN3*, BIN HE4, KAI TAN5, CHONG JIN2, HAO JIANG2, XUEFENG PAN2 and WEIDONG LIN2

1Department of Hepatobiliary Surgery, First Clinical College, Wenzhou Medical University, Wenzhou, Zhejiang 325000; 2Department of Hepatobiliary Surgery, Taizhou Central Hospital, Taizhou, Zhejiang 318000; 3Research Center of Clinical Pharmacy, State Key Laboratory for Diagnosis and Treatment of Infectious Disease, First Affiliated Hospital, Zhejiang University, Hangzhou, Zhejiang 310003; Departments of 4Gastrointestinal Surgery and 5Radiology, Taizhou Central Hospital, Taizhou, Zhejiang 325000, P.R. China

Received January 4, 2016; Accepted June 21, 2017

DOI: 10.3892/ol.2017.7058

Abstract. The present study aimed to investigate the therapeutic efficacy and clinical value of recombinant human adenovirus-p53 (rAd-p53) perfusion via the pancreatic artery for the treatment of mid-late stage pancreatic cancer. rAd-p53 (2x10^12 virus particles) in 6 ml normal saline was pushed (intravenous bolus) into the gastroduodenal and superior pancreaticoduodenal arteries via interventional superselection, with the catheter retained for subsequent drug administration at a 3-day interval for 4 cycles. Tumor changes in all patients were observed to evaluate tumor response by computed tomography (CT) at 2, 8 and 16 weeks post-treatment. The following improvements were noted in the 23-patient cohort: A total of 73.9% (17/23) of patients demonstrated significant tumor shrinkage (>20%); the symptoms of abdominal and back pain were relieved in 15 patients; the survival time was >12 months in 1 patient and >6 months in 14 patients; the patient's general condition, including appetite, was improved in 13 patients; body weight was increased in 9 patients; jaundice was attenuated in 12 patients; and ascites subsided in 13 patients; body weight was increased in 9 patients; jaundice was attenuated in 12 patients; and ascites subsided in 10 patients. However, the therapeutic outcome was poor in 2 patients whose tumors size did not show significant change after treatment as detected by CT. These 2 patients succumbed within 6 months. In conclusion, rAd-p53 perfusion via the pancreatic artery is a safe and minimally invasive option for the treatment of mid-late stage pancreatic cancer.

Introduction

Advanced-stage pancreatic cancer is the most lethal human malignancy, with an overall 5-year survival rate of <5% (1). This poor outcome is largely due to the late diagnosis, and as conventional therapeutics, including surgical resection, chemotherapy and radiotherapy, have limited efficacy (2). Although several strategies are widely used to treat advanced pancreatic cancer, such as using gemcitabine alone or in combination with other drugs, the emergence of drug resistance is becoming a problem for treating advanced pancreatic cancer (3,4).

Cellular tumor antigen p53 (p53) is an important transcription factor that activates or represses the expression of numerous genes, including those involved in cell cycle and cell survival (5,6). Previous studies have shown that p53 causes a significant antitumor effect inducing cell cycle arrest, senescence and apoptosis in response to stress stimulus such as oncogene activation and DNA damage (7-11). A recent study reported that >75% of patients with advanced pancreatic cancer possessed a tumor protein p53 (TP53) gene alteration (12). Although there have been a number of widely reported adverse events, gene therapy is becoming a new paradigm and an important part of combined therapy regimens for tumors, and has shown enormous therapeutic potential (13-15). TP53 is by far the most commonly transferred tumor suppressor gene in cancer trials (16), but clinical trials based on wild-type TP53 in patients with pancreatic cancer are lacking.

The present study demonstrated that administration of recombinant human adenovirus p53 agent (rAd-p53) could not only reduce the size of the tumor, but also relieve the symptoms induced by pancreatic cancer.

Patients and methods

Materials and methods. The present study was approved by the Ethics Committee of Taizhou Municipal Central Hospital (Taizhou, China) and conducted according to the Ethical Guidelines for Human Genome/Gene Research enacted by the Helsinki Declaration and the Chinese Government. Written informed consent was obtained from all patients. All
23 cases of patients who did not receive surgical resection were collected between January 2010 and January 2012 at the Department of Hepatobiliary Surgery of Taizhou Central Hospital (Taizhou, China). None of the patients received local or systemic treatment prior to rAd-p53 treatment.

Treatment. First, the patient was laid flat in the digital subtraction angiography room for a celiac arteriography via the right femoral artery using the Seldinger method to identify the trunk of the celiac artery. The arteriography was superselected to the gastroduodenal artery in 18 cases, and to the superior pancreaticoduodenal artery in the remaining 5 cases. A total of 4 ml rAd-p53 (2x10^{12} virus particles; Gendicine®; Benda Pharmaceutical, Inc., Wuhan, China) in 6 ml normal saline was pushed (intravenous bolus) into each patient per cycle. After sealing the indwelling catheter with heparin, the patient was sent back to the ward. rAd-p53 was administered at a 3-day interval for a total of 4 cycles, so that a total dose of 8x10^{12} virus particles were administered to each patient. Next, the perfusion catheter was removed and the incision was pressure-dressed locally.

Response evaluation. Temperature was checked three times daily, blood and urine routine three times per week, liver and kidney function was assessed three times per week, and pancreatic computed tomography (CT) was performed at 2, 8 and 16 weeks post-rAd-p53 administration.

Criteria for therapeutic effect evaluation. Therapeutic effect was graded as follows: i) Complete response (CR), disappearance of all visible lesions for at least 4 weeks; ii) partial response (PR), a >50% decrease in the product of the maximum diameter and the maximum vertical diameter of the lesion for at least 4 weeks; iii) minimal response (MR), a >25% and <50% decrease in the product of the two diameters without occurrence of new lesions; iv) stable disease (SD), a <25% decrease or a <25% increase in the product of the two diameters without occurrence of new lesions; and v) progressive disease (PD), a >25% increase in the product of the two diameters or occurrence of new lesions. The overall response rate was calculated as the CR plus the PR, without including MR and SD (17).

Statistical analysis. Statistical analysis was performed with GraphPad Prism 5.0 (GraphPad Software, La Jolla, CA, USA). Values are expressed as the mean ± standard deviation. One-way analysis of variance was used to compare the differences between the groups using Dunnett’s post hoc test. P<0.05 was considered to indicate a statistically significant difference.

Results

Patient characteristics. The present study included 23 patients diagnosed with pancreatic cancer by biopsy, including 17 males and 6 females, with a mean age of 56.8 years (Table I). The time

<table>
<thead>
<tr>
<th>Case no.</th>
<th>Sex</th>
<th>Age</th>
<th>Location</th>
<th>Size, cm</th>
<th>Jaundice</th>
<th>Pain</th>
<th>Lean</th>
<th>LM</th>
<th>BM</th>
<th>Shrinkage, %</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>68</td>
<td>Head</td>
<td>4.6x6.3</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>79</td>
<td>Body tail</td>
<td>7.0x4.3</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>3</td>
<td>M</td>
<td>73</td>
<td>Head</td>
<td>4.1x3.6</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>50</td>
<td>Head</td>
<td>4.0x2.7</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>62</td>
<td>Head</td>
<td>9.0x6.0</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>45</td>
<td>Head</td>
<td>4.3x5.0</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>7</td>
<td>M</td>
<td>53</td>
<td>Body tail</td>
<td>13.7x9.7</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>67</td>
<td>Head</td>
<td>3.4x5.5</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>9</td>
<td>F</td>
<td>82</td>
<td>Head</td>
<td>4.7x3.4</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>10</td>
<td>M</td>
<td>47</td>
<td>Head</td>
<td>5.4x4.2</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>11</td>
<td>M</td>
<td>63</td>
<td>Head</td>
<td>6.0x5.3</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>57</td>
<td>Head</td>
<td>4.7x6.3</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>13</td>
<td>M</td>
<td>48</td>
<td>Head</td>
<td>5.6x7.3</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>14</td>
<td>M</td>
<td>73</td>
<td>Head</td>
<td>4.9x6.5</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>15</td>
<td>M</td>
<td>81</td>
<td>Body</td>
<td>4.6x5.6</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>16</td>
<td>F</td>
<td>75</td>
<td>Head</td>
<td>4.5x6.3</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>17</td>
<td>M</td>
<td>57</td>
<td>Body</td>
<td>4.6x5.8</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>18</td>
<td>M</td>
<td>74</td>
<td>Body tail</td>
<td>5.2x6.7</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>19</td>
<td>M</td>
<td>68</td>
<td>Head</td>
<td>4.5x5.2</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>20</td>
<td>M</td>
<td>71</td>
<td>Head</td>
<td>5.6x6.8</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>21</td>
<td>M</td>
<td>86</td>
<td>Body tail</td>
<td>9.5x8.3</td>
<td>No</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>22</td>
<td>M</td>
<td>56</td>
<td>Body</td>
<td>5.6x4.2</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
<tr>
<td>23</td>
<td>M</td>
<td>61</td>
<td>Head</td>
<td>3.8x6.0</td>
<td>No</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
<td>No</td>
<td>8.0x10^{12}</td>
</tr>
</tbody>
</table>

rAd-p53, recombinant human adenovirus-p53; M, male; F, female; vp, virus particles; LM, lung metastasis; BM, bone metastasis.
of disease onset was 6-18 months before diagnosis. All patients reported varying degrees of abdominal pain and radiating pain to the back on admission. Of the 23 patients, 19 patients presented with jaundice, 17 patients looked extremely lean, and 5 cases were complicated with lung metastasis and 3 with bone metastasis. Of the 23 pancreatic cancer cases, 15 cases were located in the head of the pancreas arising from the uncinate process, and the remaining 8 cases were located in the junction of the head and body.

Clinical outcome. Among the 23 pancreatic cancer patients (Table I), 17 patients experienced marked tumor shrinkage (>20%), 14 patients reported relief from the abdominal and back pain (Fig. 1 and Table II). The patient’s general condition, including appetite, was improved in 13 patients, weight gain was reported in 9 patients, jaundice was lessened in 13 patients and ascites subsided in 10 patients (Table III). Clinical characteristics, including hematological profiles, and liver and kidney function, were not significantly different. The clinical outcome was poor in 2 patients, in whom a CT re-checkup showed no marked change in the tumor volume. These 2 patients succumbed within 6 months.

Discussion

Patients with pancreatic cancer, particularly mid-late stage pancreatic head cancer, often lose the opportunity for surgical intervention, while the therapeutic efficacy of chemotherapy...
and radiotherapy is usually unsatisfactory (1,18). The prognosis of these patients is extremely poor due to advanced TNM stage and is often complicated with systemic jaundice, ascites, and intolerable abdominal and back pain (19).

The key to TP53 gene therapy lies in obtaining exogenous wild-type TP53, introducing it into tumor cells, and inducing its expression in the cells safely and effectively, usually using a virus, adenovirus or liposome as the vector (4). Current studies have demonstrated that introduction of wild-type TP53 into tumor cells can induce cell cycle arrest, promote apoptosis and inhibit tumor angiogenesis, so as to cause tumor cells of various origins to undergo apoptosis, eventually resulting in tumor disappearance (20-22).

Numerous studies have indicated that the expression of TP53 is altered and frequently mutated in pancreatic cancer, which may be associated with the more malignant biological behavior of the cancer (23-26). TP53 gene therapy, particularly adenovirus-mediated rAd-p53 gene therapy, has been used for the clinical treatment of head and neck squamous cell carcinoma, with good clinical outcomes, determined by increased clinical symptoms were relieved in 21 of the 23 patients who received trans-arterial p53 perfusion therapy, suggesting that clinical treatment of head and neck squamous cell carcinoma, with good clinical outcomes, determined by increased tumor disappearance (21).

The key to TP53 gene therapy lies in obtaining exogenous wild-type TP53, introducing it into tumor cells, and inducing its expression in the cells safely and effectively, usually using a virus, adenovirus or liposome as the vector (4). Current studies have demonstrated that introduction of wild-type TP53 into tumor cells can induce cell cycle arrest, promote apoptosis and inhibit tumor angiogenesis, so as to cause tumor cells of various origins to undergo apoptosis, eventually resulting in tumor disappearance (20-22).

Numerous studies have indicated that the expression of TP53 is altered and frequently mutated in pancreatic cancer, which may be associated with the more malignant biological behavior of the cancer (23-26). TP53 gene therapy, particularly adenovirus-mediated rAd-p53 gene therapy, has been used for the clinical treatment of head and neck squamous cell carcinoma, with good clinical outcomes, determined by increased survival times (27,28). The arterial infusion approach can ensure that large amounts of the high-concentration drug can access to tumor cells, with only small amounts of the drug entering the circulation, thus maximizing the therapeutic efficacy and reducing the systemic adverse effects (29). Further laboratory tests showed that there were no significant side effects following adenovirus-mediated rAd-p53 gene therapy by the arterial infusion approach in terms of hematological profiles, and liver and kidney function. In the present study, the clinical symptoms were relieved in 21 of the 23 patients who received trans-arterial p53 perfusion therapy, suggesting that this method can be used clinically on a larger scale, although the number of cases in the study was relatively small and further clinical trials are required.

#### References